Spitzer Gudrun M, Wellenzohn Bernd, Laggner Christian, Langer Thierry, Liedl Klaus R
Theoretical Chemistry, Faculty of Chemistry and Pharmacy, University of Innsbruck, Innrain 52a, A-6020 Innsbruck, Austria.
J Chem Inf Model. 2007 Jul-Aug;47(4):1580-9. doi: 10.1021/ci600500v. Epub 2007 May 23.
The more that is known about human and other genome sequences and the correlation between gene expression and the course of a disease, the more evident it seems to be that DNA is chosen as a drug target instead of proteins which are built with the information encoded by DNA. According to this approach, small minor groove binding molecules have been designed to bind the DNA sequence specifically and thereby downregulate genes. Because of their lack of druglikeness, we plan to use them as templates for forthcoming virtual screening experiments to discover molecules with the same bioactivity and a different scaffold. In this proof of principle study, carried out with the software tool Catalyst, we present a model work for description of a ligand-DNA complex with the aid of pharmacophore modeling methods. The successful reproduction of sequence specificity of a polyamidic minor groove binding ligand is the precondition for later model application to virtual screening.
人们对人类及其他基因组序列以及基因表达与疾病进程之间的相关性了解得越多,似乎就越明显地发现,DNA被选作药物靶点,而非由DNA编码信息构建而成的蛋白质。按照这种方法,已设计出小沟结合分子,使其特异性结合DNA序列,从而下调基因。由于它们缺乏类药性,我们计划将其用作即将进行的虚拟筛选实验的模板,以发现具有相同生物活性但骨架不同的分子。在这项使用软件工具Catalyst进行的原理验证研究中,我们借助药效团建模方法,展示了一个描述配体-DNA复合物的模型工作。聚酰胺小沟结合配体序列特异性的成功再现,是该模型随后应用于虚拟筛选的前提条件。